FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT.	OF CHAI	NGES IN	RENEFICIAL	OWNERSH

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	urden							
l ba aaa aaaaa.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							- ()			1								
Name and Address of Reporting Person* McHale Duncan				2. Issuer Name and Ticker or Trading Symbol <u>Evelo Biosciences, Inc.</u> [EVLO]								Relationship of Reporting Person(s) to Issuer (Check all applicable) 100/ Chapter						
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/07/2023					X	Officer below)	,		10% Owner Other (spec below) dical Officer				
C/O EVELO BIOSCIENCES, INC. 620 MEMORIAL DRIVE					4. If Amendment, Date of Original Filed (Month/Day/Year)						Line)	Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	IDGE M	IA	02139										X		ed by Mor		rting Persor One Repor	I
(City)	(S	state)	(Zip)	 	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Та	ble I - Non	ı-Derivat	ive Se	cur	ities Ac	quired,	Dis	osed o	of, or E	Bene	ficially	Owned				
Date			2. Transact Date (Month/Day	Execution Date,		, Transaction Disposed Code (Instr.		rities Acquired (A) o			5. Amour Securities Beneficia Owned For Reported	s Form		: Direct I · Indirect I str. 4) (7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code	v	Amount (A) or)	Price	Transacti (Instr. 3 a	on(s)			msu. 4)		
Common Stock 05			05/07/2	/2023 M 130,000 A		(1)	164,246			D								
			Table II - I	Derivativ (e.g., put										Owned				
Derivative Conversion Date Ex Security or Exercise (Month/Day/Year) if a		3A. Deemed Execution Da if any (Month/Day/Y	Date, Transaction Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	e s illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	or Nu	nount ımber Shares		(Instr. 4)			
Restricted Stock Units	(1)	05/07/2023		М			130,000	(2)		(2)	Commo		30,000	\$0	390,00	00	D	

Explanation of Responses:

- 1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock
- 2. The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. These RSUs have no expiration date.

Remarks:

/s/ Marella Thorell, Attorney-in-05/09/2023 Fact for Duncan McHale

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.